Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: Results of an IFM phase II study

Haematologica

Volumn 91, Issue 11, 2006, Pages 1498-1505

  Harousseau, Jean Luc ^a   Attal, Michel ^b   Leleu, Xavier ^c   Troncy, Jacques ^d   Pegourie, Brigitte ^e   Stoppa, Anne Marie ^f   Hulin, Cyrille ^g   Benboubker, Lofti ^h   Fuzibet, Jean Gabriel ⁱ   Renaud, Marc ^j   Moreau, Philippe ^a   Avet Loiseau, Hervé ^a  

^a HÔTEL DIEU   (France)

^b CHU PURPAN   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e GRENOBLE UNIVERSITY HOSPITAL   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g CHU NANCY BRABOIS   (France)

^h UNIVERSITY HOSPITAL OF TOURS   (France)

ⁱ CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^j POITIERS UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Bortezomib; Clinical trial; Dexamethasone; Multiple myeloma; Stem cell transplantation

Indexed keywords

BORTEZOMIB; COTRIMOXAZOLE; DEXAMETHASONE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG INDUCED DISEASE; DRUG SAFETY; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 33750953054     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Harousseau JL, Moreau P, Attal M, Facon T, Avet-Loiseau H. Stem-cell transplantation in multiple myeloma. Best Pract Res Clin Haematol 2005;18:603-18.
2. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myeloma. N Engl J Med 1996;335:91-7.
3. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-83.
4. Palumbo A, Bringhen S, Petrucci MT, Musto P, Rossini F, Nunzi M, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004;104:3052-7.
5. Durie B. New approaches to treatment for multiple myeloma: durable remission and quality of life as primary goals. Clin Lymphoma Myeloma 2005;6:181-90.
6. Harousseau JL, Moreau P. Evolving role of stem cell transplantation in multiple myeloma. Clin Lymph Myel 2005;6:89-95
7. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003;349:2495-502.
8. Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, et al. Treatment of multiple myeloma. Blood 2004;103:20-32.
9. Barlogie B, Tricot G, Anaisie E, Shaughnessy J, Rasmissen E, Van Rhee F et al. Thalidornide and hematopoietic cell transplantation for multiple myeloma. N Engl J Med 2006;354:1021-30.
10. 2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Franco-phone du Myelome 9502 randomized trial. Blood 2002;99:731-5.
11. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology (Am Soc Hematol Educ Program) 2002;214-40.
12. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. Blood 2000;95:7-11.
13. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
14. Raje N, Powles R, Kulkami S, Milan S, Middleton G, Singhal S, et al. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997;97:153-60.
15. Segeren CM, Sonneveld P, van der Holt B, Vellenga E, Croockewit AJ, Verhoef GE, et al. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 2003;101:2144-51.
16. Adams J, Palombaella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
17. Adams J. The proteasome: a suitable anti-neoplastic target. Nat Rev Cancer 2004;4:349-60.
18. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
19. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72.
20. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
21. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes rug resistance in human multiple myeloma cells. Cancer Res 2001;61:3071-6.
22. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005;129:776-83.
23. Jagannath S, Durie B, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Blood 2005;106:[Abstract 783].
24. Richardson PG, Briemberg H, Jagannath S. Frequency, characteristics, and reversability of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20.
25. Avet-Loiseau H, Facon T, Daviet A, Godon C, Rapp MJ, Harousseau JL, et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999;59:4546-50.
26. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
27. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351:1860-73.
28. Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br J Haematol 1999;105:127-30.
29. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992;80:86-9.
30. Kumar S, Lacy MQ, Dispenzieri A, Rajkumar SV, Fonseca R, Geyer S, et al. Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Bone Marrow Transplant 2004;34:485-90.
31. Lahuerta JJ, Martinez-Lopez J, Serna JD, Blade J, Grande, C, Alegre A, et al. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients. Br J Haematol 2000;109:438-46.
32. Rajkumar SV, Fonseca R, Dispenzieri A, Lacy MQ, Witzig TE, Lust JA, et al. Effect of complete response on outcome following autologous stem cell transplantation for myeloma. Bone Marrow Transplant 2000;26:979-83.
33. Davies FE, Forsyth PD, Rawstron AC, Owen RG, Pratt G, Evans PA, et al. The impact of attaining a minimal disease state after high-dose melphalan and autologous transplantation for multiple myeloma. Br J Haematol 2001;112:814-9.
34. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005;106:35-9.
35. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005;106:2977-81.
36. Jagannath S, Richardson PG, Sonneveld P, Irmin D, Schuster MW, Stadtmauer EA et al. Bortezomib appears to overcome poor prognosis confered by chromosome 13 deletion in phase 2 and 3 trials. J Clin Oncol 2005;23:560s.
37. Miyakoshi S, Kami M, Yuji K, Matsumura T, Takatoku M, Sasaki M ET AL. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 2006;107:3492-4.
38. Rajkumar SV, Blood E, Vesole DH, Funseca R, Greipp PR. Phase III clinical trial of Thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006;24:431-6.
39. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005;129:755-62.
40. Bourin P, Huynh A, Recher C, Berthou C, Garderet L, Benbouker L, et al. Stem cell factor for hematopoietic stem cell mobilization: results of the randomized IFM 99-01 trial. Blood 2004;104:798a [abstract].
41. Richardson PG, Chanan-Khan A, Schlossman RL, Munshi NC, Wen P, Briemberg H, et al. A multicenter phase II trial of bortezomib in patients with previously untreated multiple myeloma: efficacy with manageable toxicity in patients with unexpectedly high rates of baseline peripheral neuropathy. Blood 2005;106:716a[Abstract].
42. Wang M, Delasalle K, Giralt S, Alexaninan R. Rapid control of previously untreated multiple myeloma with bortezomib-thalidomide-dexamethasone followed by early intensive therapy. Blood 2005;106:231a[Abstract].
43. Barlogie B, Tricot G, Rasmissen E, Anaissie E, Van Rhee F, Zangai M, et al. Total therapy 3 (113) incorporating Velcade into upfront management of multiple myeloma: comparison with TT2+Thalidomide. Blood 2005;106:337a[Abstract] .
44. Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, et al. Combination therapy with lenalidomide plus dexamethasone (REV/DEX) for newly diagnosed myeloma. Blood 2005;106:4050-3.
45. Knight R, Delap F, Zeldis J. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354:2079-80.
46. Rajkumar SV, Blood E. Lenalidomide and venous thrombosis in multiple myeloma. N Engl J Med 2006;354:2080.